Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US

Core Viewpoint - Pfizer's CEO Albert Bourla indicated that the company may consider relocating drug manufacturing back to the US if tariffs imposed by President Trump impact operations [1][7]. Group 1: Manufacturing Operations - Pfizer currently operates 13 manufacturing sites in the US, with some being large-scale facilities [2]. - The company has the capability to transfer manufacturing from overseas sites to US sites if necessary [2]. - Bourla emphasized that the US manufacturing sites are currently operating at good capacity [2]. Group 2: Political Context - Bourla expressed that he was not surprised by Trump's election victory, noting it was a significant win [3]. - He acknowledged that the new administration presents both risks and opportunities for the pharmaceutical industry [3]. - The company aims to maintain close relations with the administration to influence the regulatory environment [3]. Group 3: Tariff Implications - Trump announced plans to impose 25% tariffs on Mexico and Canada, which could affect Pfizer's operations [4]. - The Trump administration previously imposed a 10% tariff on China, with an additional 10% set to take effect soon [5]. - Bourla stated that Pfizer does not currently rely on China, Canada, or Mexico for its operations [5].